Filing Flows › Lineage Cell Therapeutics (LCTX) › Collaboration Revenues revenue
Lineage Cell Therapeutics (LCTX) Collaboration Revenues revenue by quarter
Lineage Cell Therapeutics' Collaboration Revenues revenue was $943K in Q2 2026 (second quarter 2026), -40% from Q1 2026. Over the last 3 quarters it ranged from $943K (Q2 2026) to $3.5M (Q3 2025).
| Quarter | Collaboration Revenues revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $943K | -40% | — |
| Q1 2026 | $1.6M | -56% | — |
| Q3 2025 | $3.5M | — | — |
Q2 2026 at a glance
Lineage Cell Therapeutics, Q2 2026: revenue $1.1M (-61% year over year), operating margin -834.7%, net earnings $1.5M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Lineage Cell Therapeutics' Collaboration Revenues revenue?
Lineage Cell Therapeutics' Collaboration Revenues revenue was $943K in Q2 2026 (second quarter 2026), -40% from Q1 2026.
How has Lineage Cell Therapeutics' Collaboration Revenues revenue changed?
Over the last 3 quarters it ranged from $943K (Q2 2026) to $3.5M (Q3 2025).
Q2 2026 results → · How Lineage Cell Therapeutics makes money →